Bayer Menopause Drug Meets Key Goal in Late-Stage Trial
By Adria Calatayud
Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval.
The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms, also known as hot flashes, compared to placebo. The long-term safety profile observed over 52 weeks in the phase 3 trial is overall consistent with previously conducted studies, the company said.
The study comes after Bayer reported positive results for two late-stage studies of the same drug.
Bayer said it will submit data from the studies to health authorities for approval of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 19, 2024 03:48 ET (07:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis